Director Clinical Sciences
Tango Therapeutics
Director Clinical Sciences
Tango Therapeutics
Develops synthetic-lethality cancer therapies
Company Overview
Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.
This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.
Tango is located at 201 Brookline Avenue, in the vibrant Fenway area of Boston, Massachusetts.
Summary
Tango has an exciting opportunity to join the team as our Director, Clinical Sciences. This is a hands-on role with scientific contributions to one or more clinical development programs. The successful candidate will actively engage in the design, execution, analysis, and interpretation of clinical studies. You will ensure scientific rigor throughout study conduct, lead data review and analysis, and partner cross-functionally to advance clinical development programs. This role reports to the Executive Director, Clinical Sciences.
Your Role:
What You Bring:
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
Salary range 190400 - 285600 USD
Develops synthetic-lethality cancer therapies
Tango Therapeutics develops cancer medicines by leveraging synthetic lethality to selectively kill cancer cells while sparing healthy cells. Its approach focuses on creating drugs that exploit interactions between gene pairs, aiming for targeted therapies that spare normal tissue. The company advances its treatments through a strong R&D program and collaborates with larger pharmaceutical partners, such as Gilead Sciences, to co-develop therapies and accelerate commercialization. Revenue comes from these partnerships and funding rounds like its Series B. Tango differentiates itself with a dedicated emphasis on genetically targeted cancer therapies, a robust pipeline, and leadership that guides strategic collaborations. The company’s goal is to bring next-generation, genetically targeted immunotherapies to market, improving outcomes for cancer patients by precisely targeting tumor biology.
Explore more opportunities at Tango Therapeutics